Clinical trial
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
NCT00409175 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00409175 |
|---|---|
| Title | Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis |
| Official title | Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Familial Amyloid Polyneuropathy |
| Intervention type | Drug |
| Interventions | Fx-1006A, Placebo |
| Enrollment | 128 |
| Start date | Jan 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Dec 8, 2006 |
| Last update posted | Dec 17, 2012 |
| Countries | Argentina, Brazil, France, Germany, Portugal, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: